842 results on '"Cheong, Hee Jin"'
Search Results
2. The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination
3. Real-world effectiveness of influenza vaccine over a decade during the 2011–2021 seasons—Implications of vaccine mismatch
4. Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy
5. Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines
6. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
7. Metformin reduces the risk of developing influenza A virus related cardiovascular disease
8. Risk Factors of Pertussis Among Older Adults in South Korea: A Nationwide Health Data-Based Case–Control Study
9. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
10. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea
11. Comparison of the second and third waves of the COVID-19 pandemic in South Korea: Importance of early public health intervention
12. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
13. Safe hospital preparedness in the era of COVID-19: The Swiss cheese model
14. Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis
15. COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza
16. Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis using Prefusion F and G Protein Antibodies
17. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach
18. Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination
19. Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea
20. Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea
21. Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference
22. Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines.
23. Effectiveness of Antiviral Therapy on Long COVID: A Systematic Review and Meta-Analysis
24. 907. Age-stratified seroprevalence of respiratory syncytial virus in Korean population
25. 1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
26. 1893. Mathematical modeling the impact of the age-dependent latent tuberculosis treatment on active tuberculosis in South Korea
27. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
28. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
29. Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults
30. Paradoxical long-term impact of maternal influenza infection on neonates and infants
31. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults
32. Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database
33. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
34. Clinical and microbiological characterization of serotype 6D pneumococcal infections in South Korea
35. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults
36. Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening
37. Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review
38. A Systems Vaccinology Approach Reveals the Mechanisms of Immunogenic Responses to Hantavax Vaccination in Humans
39. Incidence and Healthcare Burden of Pertussis among Older Adults with and without Pre-Existing Chronic Obstructive Pulmonary Disease or Asthma in South Korea
40. Respiratory syncytial virus infection and the need for immunization in Korea
41. Clinical implications of gut microbiota and cytokine responses in coronavirus disease prognosis
42. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
43. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial
44. Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers
45. Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes
46. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
47. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia
48. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial
49. Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
50. Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.